shingles – media

Senators Write to GlaxoSmithKline to Boost Shingrix Supply

As a result of the high demand for GlaxoSmithKline's new shingles vaccine, Shingrix, two U.S. senators have urged the pharma giant to boost inventory levels on facing a shortage in the supplies even after the company established their "fair and equitable" process to ship Shingrix doses.
- Source: FiercePharma
- 818
- July 10, 2018
Company Insight GlaxoSmithKline shingles Shingrix vaccine
Shingrix Orders Limited by GlaxoSmithKline

Order limits have been introduced by GSK owing to high demand for the product, as per a note on the CDC’s website. In the meantime, shipping delays are being experienced by providers and according to the CDC, the delays are likely to remain throughout the year.
- Source: FiercePharma
- 673
- June 22, 2018
GSK Market Views shingles
GSK’s Shingrix Gets Positive CHMP Opinion For Prevention Of Shingles

GlaxoSmithKline plc (GSK,GSK.L) said that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has issued a positive opinion recommending marketing authorisation for Shingrix (RELATED: CDC backs GSK’s Shingrix over Merck & Co’s Zostavax) for the prevention of shingles, or herpes zoster, and post-herpetic neuralgia or PHN
- Source: rttnews
- 603
- January 30, 2018
Company Insight herpes zoster PHN shingles Shingrix
Shingrix approved in the US for prevention of shingles in adults aged 50 and over

GlaxoSmithKline plc announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 50 years and older. Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses.
- Source: Gsk
- 619
- October 23, 2017
FDA New Approvals shingles vaccine
GlaxoSmithKline wins first-ever nod for blockbuster vaccine prospect Shingrix

Just as GlaxoSmithKline nears a decision from the U.S. FDA for its key shingles vaccine, Shingrix, Canada has become the first country to approve the shot—and it's a key piece of CEO Emma Walmsley's prescription for growth at the drugmaker.
- Source: fiercepharma
- 605
- October 19, 2017
New Approvals shingles vaccine

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.